logo

Immunomedics Inc. (IMMU)



Trade IMMU now with
  Date
  Headline
9/15/2017 8:02:50 AM Immunomedics Announces Agreements To Exchange About $80.0 Mln Of 4.75% Convertible Senior Notes Due 2020
9/11/2017 7:10:12 AM Immunomedics Presents Interim Phase 2 Results With Sacituzumab Govitecan (IMMU-132)
8/21/2017 8:20:10 AM Immunomedics Announces Publication Of Phase 2 Results With Labetuzumab Govitecan (IMMU-130)
5/12/2017 7:05:31 AM Company Spotlight: Immunomedics
5/5/2017 8:49:20 AM Immunomedics, Seattle Genetics Reach Mutual Agreement To Dissolve Exclusive Global Licensing Agreement
5/5/2017 8:01:55 AM Seattle Genetics Terminates License Agreement With Immunomedics For Sacituzumab Govitecan (IMMU-132)
3/15/2017 8:07:41 AM Immunomedics: MMU-132 Is Highly Active In Heavily-pretreated Patients With Metastatic Triple-negative Breast Cancer
2/10/2017 7:27:33 AM Immunomedics Postpones 2016 Annual Meeting To March 3